PIA
MDGL icon

Piedmont Investment Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Piedmont Investment Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-101
Closed -$28K – 1760
2018
Q2 		$28K Buy
+101
New +$17.7K ﹤0.01% 1480

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Piedmont Investment Advisors's MDGL Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2018, closing a stake of 101 shares — an estimated $28K sold.

Piedmont Investment Advisors first reported a position in MDGL in Q2 2018 and held it in 1 quarter. The position peaked at $28K in Q2 2018. 156 funds tracked by Wall St. Rank hold MDGL as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Madrigal Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 101 Madrigal Pharmaceuticals shares in Q3 2018, an estimated $28K.
  • Piedmont Investment Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Madrigal Pharmaceuticals position peaked at $28K in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.